Promore Pharma AB (publ) reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was SEK 7.08 million compared to SEK 8.37 million a year ago. Basic loss per share from continuing operations was SEK 0.12 compared to SEK 0.14 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
7.95 SEK | -2.45% | -5.92% | -27.81% |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-27.81% | 1.57Cr | |
+6.62% | 11TCr | |
+11.04% | 11TCr | |
-12.77% | 2.22TCr | |
+0.15% | 2.13TCr | |
-4.50% | 1.9TCr | |
-37.85% | 1.85TCr | |
-10.98% | 1.68TCr | |
+38.66% | 1.25TCr | |
-25.44% | 808.97Cr |
- Stock Market
- Equities
- PMDS Stock
- News PMD Device Solutions AB
- Promore Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2023